European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaJuan Luis Steegmann, Richard E. Clark|Leukemia|2016Cited by 473
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upRichard A. Larson, H. Kantarjian, Andreas Hochhaus et al.|Leukemia|2012Cited by 440
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European CountriesVerena Hoffmann, Rüdiger Hehlmann, Hele Everaus et al.|Leukemia|2015Cited by 255
Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challengeC. Breathnach, D.P. Lunn, Heather Clark et al.|Vaccine|2005Cited by 77
HLA‐A3 increases and HLA‐DR1 decreases the risk of acute graft‐versus‐host disease after HLA‐matched sibling bone marrow transplantation for chronic myelogenous leukaemiaRichard E. Clark, Jo Hermans, J. Alejandro Madrigal et al.|British Journal of Haematology|2001Cited by 23